Chemoprevention in the 21st century: Is a balance best or should women have no estrogen at all?

Journal of Clinical Oncology

Volumn 23, Issue 8, 2005, Pages 1598-1600

  Jordan, V Craig ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG SAFETY; EDITORIAL; ENDOMETRIUM CANCER; HEALTH CARE DELIVERY; HISTORY OF MEDICINE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; ADOLESCENT; ADULT; ANIMAL; BREAST TUMOR; FEMALE; MOUSE; RAT;

ADOLESCENT; ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; MICE; RATS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 15544386048     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.12.016     Document Type: Editorial

References (23)

1. Jordan VC, Gapstur S, Morrow M: Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 93:1449-1457, 2001
2. Goss P, Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19:881-894, 2001
3. Lerner LJ, Jordan VC: The development of antiestrogens for the treatment of breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 50:4177-4189, 1990
4. Jordan VC: Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem 46:883-908, 2003
5. Jordan VC: Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem 46:1082-1111, 2003
6. The ATAC Trialist Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet 359:2131-2139, 2002
7. Goss PE, Ingle JN, Marino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
8. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
9. Jordan VC: Tamoxifen: A most unlikely pioneering medicine. Nat Rev Drug Discov 2:205-213, 2003
10. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321-333, 2002
11. Lacassagne A: Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer 27:217-225, 1936
12. Jordan VC, Lababidi MK, Langan-Fahey S: Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 83:492-496, 1991
13. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
14. Sporn MB, Dunlop NM, Newton DL, et al: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332-1338, 1976
15. Sporn MB: Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36:2699-2702, 1976
16. Baumler E, Ehrlich P: Scientist for life. New York, Holmes & Meier, 1984
17. Jordan VC: Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 5:354, 1974
18. Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA- induced rat mammary carcinomata. Eur J Cancer 12:419-424, 1976
19. Jordan VC, Dix CJ, Allen KE: The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. Adjuvant Therapy of Cancer 2:19-26, 1979
20. Jordan VC, Allen KE: Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16:239-251, 1980
21. Jordan VC, Allen KE, Dix CJ: Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 64:745-759, 1980
22. Cuzick J, Baum M: Tamoxifen and contralateral breast cancer. Lancet 2:282, 1985
23. Powles TJ, Hardy JR, Ashley SE, et al: A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60:126-131, 1989